MedTrace Logo

Dialysate Sodium Lowering Trial

NCT03144817 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2019-06-03

No results posted yet for this study

Summary

This is a pilot randomized clinical trial in which patients treated with 3X per weekly conventional hemodialysis will be treated to a dialysate sodium 135 mEq/L vs. 138 mEq/L and followed for safety and tolerability, effects on BP and volume.

Conditions

  • Hemodialysis Complication
  • Fluid Overload
  • Dialysis Disequilibrium
  • Intra-dialytic Hypotension
  • Hypertension

Interventions

OTHER

Dialysate Sodium Lowering

Dialysate sodium is lowered until nadir sodium level is reached. Participant dialyzes at this sodium level until end of follow-up.

Sponsors & Collaborators

  • Dialysis Clinic, Inc.

    collaborator INDUSTRY

  • InBody

    collaborator UNKNOWN

  • Tufts Medical Center

    lead OTHER

Principal Investigators

  • Dana Miskulin, MD · Tufts Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-26
Primary Completion
2018-12-19
Completion
2019-04-02

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03144817 on ClinicalTrials.gov